Sacituzumab Govitecan
Gilead to withdraw Trodelvy accelerated approval for bladder cancer
Gilead Sciences announced its intention to voluntarily withdraw the accelerated approval for sacituzumab govitecan-hziv for treatment of certain patients with advanced bladder cancer.
Breast Cancer Awareness Month: New insights into lymphedema, genetic testing and AI
Breast Cancer Awareness Month is observed every October.
Drug shows ‘very promising’ activity in breast cancer brain metastases
Sacituzumab govitecan-hziy exhibited efficacy as therapy for two traditionally difficult-to-treat populations, according to results of a window-of-opportunity trial.
VIDEO: Precision medicine ‘evolving’ in metastatic breast cancer
Healio spoke with Paolo Tarantino, MD, about FDA approvals in metastatic breast cancer.
VIDEO: Important areas of future research for triple-negative breast cancer
Healio spoke with Wendy Chen, MD, MPH about recent advancements in metastatic triple-negative breast cancer.
VIDEO: Challenges of treating metastatic triple-negative breast cancer vs. other breast cancers
Healio spoke with Wendy Chen, MD, MPH about recent advancements in metastatic triple-negative breast cancer.
VIDEO: Optimizing treatment approach after chemotherapy in triple-negative breast cancer
Healio spoke with Wendy Chen, MD, MPH about recent advancements in metastatic triple-negative breast cancer.
VIDEO: Navigating the conversation after diagnosis of metastatic triple-negative breast cancer
Healio spoke with Wendy Chen, MD, MPH about recent advancements in metastatic triple-negative breast cancer.
VIDEO: Combination therapies showing promise in metastatic triple-negative breast cancer
Healio spoke with Wendy Chen, MD, MPH about recent advancements in metastatic triple-negative breast cancer.
Phase 3 study of Trodelvy for advanced lung cancer misses primary endpoint
A randomized phase 3 study designed to assess sacituzumab govitecan-hziy for treatment of previously treated metastatic non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.